Cinfa Biotech to present at two upcoming biosimilar conferences to discuss clinical development strategies

Pamplona, Spain, February 9, 2016

Cinfa Biotech S.L., the biosimilars company of Infarco group, today announced that it will present at the following biosimilar conferences:

Biosimilar Drug Development World Europe 2016

Date: February 10, 2016, 3:45 pm CET (2:45 pm GMT)
Venue: Fairmont Rey Juan Carlos, Barcelona, Spain
Dr Karsten Roth, Director Clinical Operations of Cinfa Biotech will speak on “Clinical
development strategies for Biosimilars”.

8th BIOSIMILARS Congregation 2016

Date: March 9, 2016, 1:50 pm CET (12:50 pm GMT)
Venue: Pestana Chelsea Bridge Hotel, London, UK
Dr Karsten Roth, Director Clinical Operations of Cinfa Biotech will speak on “Clinical
development strategies; a mid-size pharma perspective”.

About Cinfa Biotech

Cinfa Biotech is headquartered in Pamplona, Spain, with offices in Munich, Germany. The company was founded in 2013 and received an initial investment of EUR 70 million from its parent company Infarco to create a pipeline of biosimilar drugs to address thegrowing need for affordable therapies based on proven science, quality, safety and efficacy. A complete team of experts with decades of in-depth experience is developing biosimilars for a range of indications.

The first product candidate in clinical development is B12019, a biosimilar version of Neulasta® (pegfilgrastim). The commercialisation models will be customised to the needs of partners and markets. Product development, clinical studies, manufacturing and quality control at Cinfa Biotech are conducted in Europe according to the highest European standards.

About Infarco – parent company of Cinfa Biotech

Infarco, the parent company of Cinfa Biotech, holds a portfolio of pharmaceutical companies. With 50 years’ experience, Infarco represents the successful professional approach of a group of pharmacists to recover the central role of pharmacists in the
pharmaceutical industry. The Company today employs over 1,200 people and reinvests an average of 90% of its annual profits in its portfolio companies, thereby driving their development and innovation.

For more information please visit:

For press enquiries:

MC Services AG

Julia von Hummel, Kaja Skorka

Phone: +49 89 210 228-0

Email: Julia.vonHummel[at]

Email: kaja.skorka[at]

Shaun Brown

Phone: +44-20-71485998

Email: shaun.brown[at]

Download as PDF